Detailed price information for Pelthos Therapeutics Inc (PTHS-A) from The Globe and Mail including charting and trades.

LONDON--(BUSINESS WIRE)--Technavio analysts forecast the global impetigo market to grow at a CAGR of 7% during the forecast period, according to their latest market research report. The growth ...

EMERYVILLE, Calif., Dec. 6, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the ...

The US Food and Drug Administration (FDA) has approved ozenoxacin cream (Xepi Cream, Medimetriks Pharmaceuticals Inc) 1% for impetigo in patients aged 2 months and older. Ozenoxacin cream is a ...

DUBLIN--(BUSINESS WIRE)--The "Global Impetigo Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To ...

Xepi is indicated for the topical treatment of impetigo due to S. aureus or S. pyogenes in adult and pediatric patients. The Food and Drug Administration (FDA) has approved Xepi (ozenoxacin cream; ...

Although NovaBay ( NBY) is a small company as judged by its $37 million market capitalization, it is complex to analyze. It is developing one molecule, NVC-422, for three separate indications, ...

WAYNE, Pa., March 5, 2018 /PRNewswire/ -- Cutanea Life Sciences, Inc. has acquired the exclusive US commercialization rights for Xepi™ (ozenoxacin) Cream, 1% from Medimetriks Pharmaceuticals, Inc.

Company to have a strong onsite presence at the world’s largest scientific conference for dermatologists, with approximately 10,000 medical professionals expected to attend WOBURN, Mass., March 17, ...

SALISBURY — Two students at Salisbury High School have contracted a “contagious bacterial infection,” school officials said Wednesday. In a ConnectEd message, Principal Luke Brown said only that there ...